Pregnancy outcome after magnetic resonance–guided focused ultrasound surgery (MRgFUS) for conservative treatment of uterine fibroids

2010 ◽  
Vol 93 (1) ◽  
pp. 199-209 ◽  
Author(s):  
Jaron Rabinovici ◽  
Matthias David ◽  
Hidenobu Fukunishi ◽  
Yutaka Morita ◽  
Bobbie S. Gostout ◽  
...  
2010 ◽  
Vol 65 (5) ◽  
pp. 316-318 ◽  
Author(s):  
Jaron Rabinovici ◽  
Matthias David ◽  
Hidenobu Fukunishi ◽  
Yutaka Morita ◽  
Bobbie S. Gostout ◽  
...  

2018 ◽  
Author(s):  
Bijan J. Borah ◽  
Elizabeth A. Stewart

Uterine leiomyomas (fibroids) affect 20–40% of reproductive age women and are the major indication for hysterectomy. Magnetic Resonance-guided Focused Ultrasound Surgery (MRgFUS) is a new, potentially disruptive, non-invasive and uterine-sparing treatment option that has been shown to yield similar or better clinical outcomes than other uterine-sparing interventions. However, the costs of MRgFUS and other minimally-invasive treatment options have not been studied using US practice data. This study attempts to fill this void. And since uterine fibroids are the first FDA-approved indication for MRgFUS treatment, this study may also have implications for other indications which are now investigational.


Sign in / Sign up

Export Citation Format

Share Document